| 纯度 | ＞90% by SDS-PAGE. |
| 种属 | Human |
| 靶点 | ACBD6 |
| Uniprot No | Q9BR61 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-282aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMASSFLP AGAITGDSGG ELSSGDDSGE VEFPHSPEIE ETSCLAELFE KAAAHLQGLI QVASREQLLY LYARYKQVKV GNCNTPKPSF FDFEGKQKWE AWKALGDSSP SQAMQEYIAV VKKLDPGWNP QIPEKKGKEA NTGFGGPVIS SLYHEETIRE EDKNIFDYCR ENNIDHITKA IKSKNVDVNV KDEEGRALLH WACDRGHKEL VTVLLQHRAD INCQDNEGQT ALHYASACEF LDIVELLLQS GADPTLRDQD GCLPEEVTGC KTVSLVLQRH TTGKA |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACBD6重组蛋白的假设参考文献示例(注：部分信息为示例性概括，建议通过学术数据库核实具体文献)：
---
1. **标题**: *Recombinant ACBD6 Protein Expression and Its Role in Acyl-CoA Binding*
**作者**: Smith J, et al.
**摘要**: 本研究通过大肠杆菌系统成功表达并纯化了重组ACBD6蛋白，证实其能够特异性结合长链酰基辅酶A，并揭示了其在细胞脂质转运中的潜在功能。
2. **标题**: *Structural Characterization of Human ACBD6 Using Cryo-EM*
**作者**: Lee H, et al.
**摘要**: 通过冷冻电镜技术解析了ACBD6的三维结构，发现其N端结构域与酰基辅酶A结合相关，C端可能参与蛋白质相互作用，为靶向药物设计提供了结构基础。
3. **标题**: *ACBD6 Knockdown Alters Golgi Morphology and Lipid Homeostasis*
**作者**: Garcia R, et al.
**摘要**: 利用重组ACBD6蛋白进行体外功能实验，发现其缺失会导致高尔基体结构异常和鞘脂代谢紊乱，提示ACBD6在细胞器膜动态调控中的关键作用。
4. **标题**: *ACBD6 as a Novel Biomarker in Hepatocellular Carcinoma*
**作者**: Chen L, et al.
**摘要**: 通过重组ACBD6制备抗体，验证其在肝癌组织中显著高表达，且与患者预后相关，可能成为潜在的诊断标志物。
---
建议通过 **PubMed** 或 **Web of Science** 以关键词“ACBD6 recombinant”或“ACBD6 function”检索最新研究，以获取真实文献数据。
ACBD6 (Acyl-CoA Binding Domain-Containing Protein 6) is a member of the ACBD protein family, characterized by a conserved acyl-CoA binding (ACB) domain that facilitates interactions with acyl-CoA esters, key intermediates in lipid metabolism. This ubiquitously expressed protein is implicated in cellular processes such as lipid biosynthesis, intracellular trafficking, and maintenance of organelle integrity. While its exact physiological role remains under investigation, ACBD6 is thought to regulate the spatial distribution or activity of acyl-CoA species, potentially influencing membrane dynamics, signaling pathways, or protein modifications dependent on lipid substrates.
Recombinant ACBD6 protein is produced via genetic engineering, typically using bacterial (e.g., *E. coli*) or eukaryotic expression systems, to enable large-scale purification for functional studies. Its recombinant form retains the ACB domain's ability to bind acyl-CoA, making it a valuable tool for in vitro assays exploring lipid-protein interactions, enzymatic activities, or structural analyses. Researchers utilize this protein to investigate ACBD6's role in diseases linked to lipid dysregulation, including metabolic syndromes, neurodegenerative disorders, and cancers. For instance, altered ACBD6 expression has been observed in certain tumors, suggesting potential involvement in cancer cell proliferation or survival.
Current studies focus on deciphering ACBD6's interactome, subcellular localization (e.g., Golgi apparatus, peroxisomes), and post-translational modifications. Its recombinant version also aids in drug discovery, serving as a target for screening compounds that modulate acyl-CoA metabolism. Despite progress, comprehensive mechanistic insights into ACBD6's biological functions and therapeutic relevance remain limited, necessitating further exploration using recombinant protein-based approaches.
×
